OTTAWA, Oct. 31 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP) (“PharmaGap” or “the Company”), a Canadian biotechnology company, today announced that it has entered into an agreement with Memorial Sloan-Kettering Cancer Center (“Sloan-Kettering”). Sloan-Kettering researchers, led by Dr. Gary K. Schwartz, will study PharmaGap’s novel preclinical cancer drug, PhGalpha1, in a series of collaborative in vitro and in vivo (animal) studies to assess its efficacy and potency as a specific inhibitor of protein kinase C alpha (“PKCalpha”). PKCalpha, which is a major component of cellular signal transduction pathways, is expressed in many types of tumors, including colorectal cancer, non-small cell lung cancer, breast cancer and certain gastric cancers and therefore represents a new target for cancer therapy.
